I'll just try to go over some of those quickly because there are probably a number. Mostly, though, what they stem from is that ultimately the changes in the bill would expand what is now fairly limited, and limited in design, around getting medicines to developing countries that need them for humanitarian purposes or on certain emergencies. It would broaden that to allow for shipments without any limit in quantity, without any of the markings and other requirements that are currently in CAMR that would allow for the identification of medicines if they happened to come back into Canada accidentally or deliberately.
What you could end up seeing is products diverted either to other countries for commercial reasons, countries like Mexico or Hungary or Poland, or Singapore, where really they're not needed for humanitarian reasons, so for commercial reasons, or you could see the medicines potentially coming back to Canada as well and being indistinguishable from Canadian medicines.
By making the Health Canada review optional, you could also see medicines that haven't been through Health Canada's safety review shipped to other countries, to developing countries, without the same kind of rigorous health and safety regime that Canadians benefit from.